Surufatinib in Advanced Well-Differentiated Neuroendocrine Tumors: A Multicenter, Single-Arm, Open-Label, Phase Ib/II Trial

Xu, JM; Li, J; Bai, CM; Xu, N; Zhou, ZW; Li, ZP; Zhou, CC; Jia, R; Lu, M; Cheng, YJ; Mao, CY; Wang, W; Cheng, K; Su, CX; Hua, Y; Qi, C; Li, J; Wang, W; Li, K; Sun, QL; Ren, YX; Su, WG

Xu, JM (reprint author), Gen Hosp Peoples Liberat Army, Med Ctr 5, Beijing 100071, Peoples R China.

CLINICAL CANCER RESEARCH, 2019; 25 (12): 3486

Abstract

Purpose: No antiangiogenic treatment is yet approved for extrapancreatic neuroendocrine tumors (NET). Surufatinib (HMPL-012, previously named sulfatin......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索